T he mesothelium is a flat epithelial lining of the peritoneal, pleural, and pericardial cavities. The mesothelium is a multifunctional surface that shares many morphologic and functional properties with the endothelium-among them, molecule and electrolyte transport, anti-adherence functions, and implication in acute and chronic peritoneal inflammation (1, 2) .
Nitric oxide is a gas generated in the endothelium by the metabolic conversion of L-arginine to L-citrulline by endothelial nitric oxide synthase (eNOS) (3) . The loss of the ability of endothelium to release NO results in vascular abnormalities including vasoconstriction, smooth muscle proliferation, activation of blood elements, and increased synthesis of extracellular matrix (4) (5) (6) . Most NO-dependent effects are related to the activity of its intracellular receptor, soluble guanylate cyclase (sGC).
Initially eNOS was considered constitutive; later, inflammatory conditions [cytokines and lipopolysaccharide (LPS) particularly] were demonstrated to downregulate eNOS expression in cultured endothelial cells and in human peritoneal endothelial and mesothelial cells, by destabilizing eNOS mRNA (7) (8) (9) . Also, modifications in sGC activity have been found in the vascular wall of aging rats (10) and modifications in sGC expression have been found in experimental models of myocardial infarction (11) . The heterodimer sGC is composed of a large (α1) and a small (β1) subunit (12) . Recent cloning and expression experiments have revealed that although the α1 subunit and β1 subunit both seem to contain a catalytic domain, enzymatic activity requires the presence of both subunits (13) . Although the existence of sGC has been identified in rat peritoneal eosinophils (14) , its presence has not, to our knowledge, been described in human peritoneal tissue.
Although acetylsalicylic acid (aspirin) inhibits the synthesis of prostaglandins, the mechanisms of its anti-inflammatory properties remain unresolved. In this sense, much higher doses of aspirin are required to treat inflammatory diseases than are required to inhibit prostaglandin synthesis (15 
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PERITONEAL TISSUE
Samples of peritoneum were obtained from hernia sacs removed during indirect surgical hernia repairs. All patients gave oral informed consent. The peritoneum was carefully approached from the antemesothelial side. Routine pathologic examination of the visceral peritoneum disclosed signs of inflammation linked to neoplastic extension or diffuse ischemic lesions. The samples were quickly isolated with a curved surgical clamp and cut. We tried to avoid undue manipulation, particularly extended exposition and surgical handling, which usually causes tissue disruption. Peritoneal samples were washed with isotonic saline to remove the remaining blood and were cut into portions. The peritoneal portions were pre-incubated for 1 hour in RPMI medium containing 10% fetal calf serum (FCS), 5 mmol/L glutamine, 2×10 5 U/L penicillin, and 2×10 5 µg/L streptomycin. The medium was then removed and replaced with fresh RPMI medium containing 10% FCS. Peritoneal samples were then stimulated for 24 hours with LPS (10 µg/mL) in the presence and absence of aspirin in increasing concentrations (0.5 -10 mmol/L).
WESTERN BLOT ANALYSIS
Western blotting was used to analyze eNOS protein and sGC in the human peritoneum as previously described (16) . Human peritoneal samples were homogenized and lysed in Laemmli buffer containing 2-mercaptoethanol (17) . Equal amounts of protein (20 µg per lane) estimated by bicinchoninic acid reagent (Pierce Chemical Company, Rockford, IL, U.S.A.) were loaded. To verify that equal amounts of protein had been loaded in the gel, a parallel gel with identical samples was run and stained with Coomassie (Pierce Chemical Company) to compare the intensities of the protein bands. Proteins were separated on denaturing sodium dodecylsulfate (10%) polyacrylamide gels and blotted into nitrocellulose as previously described (16) . Western blot analysis was performed with monoclonal antibodies against eNOS and the β1 subunit of sGC. Blots were incubated with the first antibody (1:2500) for 1 hour at room temperature and, after extensive washing, with the second antibody (horseradish peroxidase-conjugated anti-mouse immunoglobulin antibody) at a dilution of 1:1500 for another hour. Specific eNOS and β1 sGC subunit proteins were detected by enhanced chemiluminescence [(ECL) Amersham Iberica, Madrid, Spain]. Prestained protein markers were used for molecular mass determinations. ARRIERO et al. ASPIRIN AND NO/CYCLIC GMP SYSTEM IMMUNOHISTOCHEMISTRY Immunohistochemistry was also used to detect eNOS expression. Human peritoneal tissue pieces were incubated with LPS in the presence and the absence of aspirin for 24 hours. The pieces were then dehydrated using sequentially increasing concentrations of ethanol followed by xylene and were embedded in paraffin wax. Paraffin blocks were sectioned at 4 µm on a standard rotary microtome (Leitz 1512: Microm Laborgeräte GmbH, Walldorf, Germany). Sections were stained with hematoxylin and eosin using an automated staining system. The sections were then incubated with a monoclonal antibody against eNOS protein. The sections were washed in phosphate-buffered saline (PBS) containing 0.05% bovine serum albumin, and then incubated with biotinylated antiserum to goat immunoglobulin G (IgG) at 1:300 dilution (Vector Laboratories Inc., Burlingame, CA, U.S.A.) for 1 hour and in a solution of peroxidase-linked avidin biotinylated enzyme complex (ABC kit: Vector Laboratories Inc.) for another hour as previously reported (18) . To reveal the peroxidase activity, the nickel-enhanced diaminobenzidine procedure was used.
STATISTICAL METHODS
Results are expressed as mean ± standard error of mean. Unless otherwise stated, each value corresponds to a minimum of six separate experiments. To determine the statistical significance of our results, we performed an ANOVA with the Bonferroni correction for multiple comparisons, or a Student t-test (paired or unpaired). A p value less than 0.05 was considered statistically significant.
RESUL RESUL RESUL RESUL RESULTS TS TS TS TS eNOS PROTEIN EXPRESSION: EFFECT OF ASPIRIN
As previously demonstrated (8), Western blot analysis using a specific monoclonal antibody against eNOS demonstrated the presence of a 140-kDa band in the homogenate of human peritoneum, indicating the presence of an eNOS-like protein that decreased with incubation with LPS (10 µg/mL) (Figure 1) . A marked decrease in eNOS protein expression was found 6 hours after exposure to LPS, and the maximum decrease in eNOS protein expression was observed after 24 hours (Fig 1) . As shown in Figure 2 , aspirin prevented the reduction in eNOS protein expression induced by LPS in human peritoneum. The protective effect of aspirin depended on its concentration. A slight increase in eNOS protein expression was observed at 1 mmol/L aspirin. Doses of aspirin lower than 1 mmol/L failed to consistently affect eNOS pro- (Figure 2 ). That dose of aspirin was then used for most of the subsequent experiments.
The specificity of the eNOS monoclonal antibody was further studied. The monoclonal antibody did not cross-react with the neuronal-type constitutive isoform (155 kDa) because the nNOS protein band was undetectable in a homogenate of rat pituitary that previously was positively stained with monoclonal antibody against the neuronal-type NOS isoform. The monoclonal antibody that was used specifically recognized the eNOS isoform expressed in homogenates of human umbilical endothelial cells (Figure 3 ).
IMMUNOLOCALIZATION OF eNOS PROTEIN
The distribution of eNOS protein was studied before and after 24 hours of exposure to LPS. Positive staining for eNOS protein was observed in peritoneal capillary endothelium and in mesothelium [ Figure 4(A) ]. This result was confirmed by the fact that eNOS protein was co-localized in cells positively stained by HBME-1, an anti-human mesothelial cell antibody (Dako Corporation, Glostrup, Denmark) that reacts with an incompletely characterized membrane antigen present on the microvillus surface of mesothelial cells (19) . These cells were negatively stained by factor VIII, suggesting the presence of mesothelial cells. Furthermore, eNOS was also expressed in cells positively stained by factor VIII and unstained by HBME-1, indicating the presence of endothelial cells. The histologic examination also revealed that LPS reduced eNOS protein expression in peritoneal endothelial and mesothelial cells alike [ Figure 4(B) ].
In samples of peritoneum, exposure to aspirin (5 mmol/L) and LPS (10 µg/mL) recovered eNOS protein expression in the capillary endothelium and in submesothelial cells [ Figure 4 (C)]. The submesothelial cells positively stained for eNOS were unstained by factor VIII and HBME-1, but were positively stained by CD34, a 110-kDa transmembrane cell-surface Western blot analysis demonstrated the presence of sGC in the peritoneal tissue. Incubation with LPS induced a marked reduction of sGC β1 subunit protein expression in the human peritoneal tissue samples ( Figure 5 ). Aspirin at 5 mmol/L prevented the downregulation of sGC β1 subunit protein expression induced by LPS ( Figure 5 ). The specificity of the antibody to sGC β1 subunit was previously assessed by recognition, in a human platelet lysate, of a 70 kDa band corresponding to sGC β1 subunit protein (Figure 5) . No changes in the β-actin expression were observed between the control and either the LPS-incubated or the LPS + aspirin-incubated samples of human peritoneum ( Figure 5 ).
DISCUSSION
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In a previous study, we demonstrated that expression of eNOS protein in human peritoneal tissue is modulated by LPS (8) . In the present study, we show that the presence of aspirin prevents the downregulation of eNOS protein expression by LPS in human peritoneum. In addition, human peritoneal tissue samples expressed the main receptor of NO (sGC), and that expression was downregulated by LPS and was protected by aspirin.
Aspirin prevented eNOS protein expression in the peritoneal tissue in a dose-dependent manner. Aspirin protected eNOS expression in peritoneal endo- Previous studies have postulated that the mesothelial cell layer is reconstituted by differentiation of submesothelial fibroblastic cells toward mesothelium (21, 22) . Accordingly, the immunohistochemical analysis suggested that the protective action of aspirin with regard to LPS-injured peritoneal membrane may occur by promoting the differentiation of submesothelial fibroblasts toward mesothelial properties. Loss of eNOS expression in peritoneal cells could compromise various cellular functions. In this regard, peritoneal inflammation is associated with increased infiltration by blood cells, and NO has been demonstrated to limit the expression of several adhesion molecules (23, 24) . Recent studies have also demonstrated that NO contributes to the regulation of fibrinolytic activity (25, 26) . In this sense, the blockade of NO synthesis stimulates the generation of plasminogen activator inhibitor (26) . Therefore, a situation of peritoneal dysfunction, in terms of a reduced ability of the peritoneum to express eNOS, could favor changes in the activity of the peritoneal fibrinolytic system.
Peritoneal tissue also expresses the main receptor of NO and the mediator of its action: sGC. Our results also suggest that, independently of the ability of the peritoneal tissue to generate NO, the sGC system was downregulated by LPS, an effect that was markedly prevented by aspirin. Therefore, aspirin protected the entire NO-cyclic guanosine-3′,5′-monophosphate (cGMP) system in the peritoneal tissue. Recent studies in cultured smooth muscle cells, fibroblasts, and pheochromocytoma cells have demonstrated that cyclic adenosine monophosphate (cAMP)-stimulating agents and the ras family of GTPases decrease sGC expression (27, 28) . Several studies have also demonstrated the ability of aspirin to prevent the inflammatory response, including release of cytokines and inflammatory prostaglandins, which, by enhancing cAMP levels could be involved in the observed downregulation of sGC related to LPS in peritoneal tissue (29) . Further studies are warranted to analyze these hypotheses.
CONCLUSION CONCLUSION CONCLUSION CONCLUSION CONCLUSION
Lipopolysaccharide downregulated both eNOS and sGC protein expression in human peritoneal tissue. Aspirin protected both eNOS and sGC protein expression in the peritoneal tissue. A better understanding of the regulatory mechanism of eNOS expression in peritoneal cells and knowledge of the mechanisms by which aspirin protected the expression of the eNOS protein in the peritoneum may lead to new pharmacologic strategies for the prevention of the peritoneal dysfunction associated with peritoneal inflammation. 
